iBio Inc. (IBIO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, iBio Inc. scores 23 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 3 / 20. The rating cites ROIC of -35% and FCF yield of 0%. For an investor, this means the business is not currently generating cash returns on capital; any upside depends on future operational change rather than existing earnings power.
• Whale 13F Flow: 4 / 20. Institutional accumulation and options positioning scored weakly. The rating does not provide a breakdown, so the investor should not infer institutional confidence from this pillar.
• Insider Conviction: 5 / 20. SEC Form 4 and Congressional PTR cluster flow scored weakly. Recent news references a director option grant, but the rating does not characterize it as a conviction signal.
• Macro Regime Fit: 6 / 20. Beta of 1.0 and sector sensitivity were scored. A beta of 1.0 means the stock is sensitive to broad market moves at the same magnitude as the market, without a cushion from its own fundamentals.
• Forensic Balance Sheet: 5 / 20. Per the rating, Altman Z is 0.2, Piotroski F is 4/9, and Debt/Equity is 0.5. These readings signal elevated financial distress risk, which is the core reason the rating carries a "Forensic Risk" label.

Taken together, the valuation tradeoff is stark: at a market cap of $52.3M against operating margin of -60% and net margin of -60%, the equity is priced on expectations rather than demonstrated cash generation. Upside drivers would need to come from catalysts that change the cash trajectory; the rating itself indicates the present fundamentals do not support that view. The 52-week range of $0.69 to $3.82 against a current price of $0.81 illustrates how far the stock has already retraced, which underscores volatility rather than confirming a floor.

Per the SEC financials, revenue has remained minimal across the three reported periods while operating losses persisted. Per the market data, gross margin is 0%, operating margin -60%, and net margin -60%, with ROIC at -35%. The Roarable RQD rating reports an Altman Z-Score of 0.2 and a Piotroski F-Score of 4/9, both consistent with financial stress. The rating reports Debt/Equity of 0.5, but debt values are absent from the SEC financials ("N/A"), so the balance sheet posture cannot be fully reconstructed from the source data. Reported cash rose from $7.0M in FY 2024 to $28.7M in FY 2025.

Per the recent news feed:

• Market wire (2026-10-07): An item references a presentation at the 2026 EASD Annual Meeting, flagged YELLOW.
• Catalyst (TradingView): A 12-month price target raise to $5.6, implying 509% upside, flagged GREEN. The source is a third-party target report, not a company disclosure.
• Market wire (The Globe and Mail): Shareholders approved governance and capital structure changes, flagged YELLOW. The source does not specify the terms.
• Risk watch (BioPharm International): Coverage of the Activin E antibody IBIO-610 in obese primates shifting semaglutide weight loss toward fat, flagged RED. This is preclinical-context reporting in the source headline and summary.
• Risk watch (TradingView): A 12-month price target cut to $5.53, implying 447% upside, flagged RED.
• Market wire (Stock Titan): A director received 38,000 options at a $0.78 exercise price, flagged YELLOW.

The butterfly supply-chain graph reports supply_chain as NONE, with no butterfly links and no proprietary signals.

• What is the company's revenue source and product pipeline, given revenue of $0.4M against operating losses of $18.6M in FY 2025?
• What are the debt levels, since the financials report debt as N/A while the rating cites Debt/Equity of 0.5?
• What terms were approved in the shareholder governance and capital structure changes, and do they involve dilution?
• How much cash runway remains at the current operating loss rate, given reported cash of $28.7M?
• Which analyst firms issued the price target changes, and what assumptions drive a 447% to 509% implied upside?